Is N-Acetyl Semax Amidate approved as a medicine, and where?

The regulatory review of N-Acetyl Semax Amidate is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.

Does N-Acetyl Semax Amidate have human clinical trials?

The evidence review of N-Acetyl Semax Amidate is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Index by category›

Nootropic & Neuropeptides

N-Acetyl Semax Amidate

Name: N-Acetyl Semax Amidate
Creator: PeptideInfo Wiki editorial collective
Published: 2026-10-07

NA-Semax Amidate; NA-Semax; N-acetyl semax amidate; Ac-Semax-NH2; HY-P3588; EX-A13574

2 min read · Updated October 7, 2026 · 6 references

Curated by PeptideInfo Wikilast reviewed October 7, 2026how we verify

In brief · TL;DR

Source record — verification pending

Chemically defined Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2 research chemical. Not the same as parent Semax (Russia-registered). No peer-reviewed data on the exact double-capped analog. Nearby Ac-only lab papers are not this product — one even lost Cu-protection vs Semax in cells. No dose.

Evidence: Catalog coverage only; independent identity, evidence and regulatory review is still pending.

Double cap: N-acetyl + C-terminal amide; PubChem CID 172638603; formula C39H54N10O10S; MW 855.0; CAS synonym 2920938-90-3
Parent Semax (CID 9811102) is Russia-registered — that status does NOT apply to this analog
No PubMed clinical or in-vivo pharmacology hit for the exact amidate product name (2026-10-07 dossier)
Ac-only papers (e.g. PMID 27586814, 23652441) are NOT documented C-amidate and must not be equated with vendor NA-Semax Amidate
Vendor better/longer Semax claims are unverified; dosing.established false

↓ Read the full referenced entry below

Facts at a glance

N-Acetyl Semax Amidate

Class: Double-capped synthetic heptapeptide analogue of Semax (Ac + C-amide)
Status: Research chemical — exact analog lacks peer-reviewed pharmacology; editorial review pending
Sequence: Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2 (N-acetyl + C-terminal amide)
Mol. weight: 855.0 (C39H54N10O10S; PubChem CID 172638603). Parent Semax ~813.9 (CID 9811102).
Half-life: Not established for this exact analog in peer-reviewed human or animal PK
Form: Research powder / vendor research peptide (not a registered medicine)

Dosing

No established dose. No approved or trial-defined regimen exists for N-Acetyl Semax Amidate. No vendor or parent-Semax dose is reproduced here.

Research areas

Peptide capping / metabolic stability hypotheses (unverified for this exact analog) · Parent Semax BDNF/neuroprotection literature — see Semax page; not transferable by default

N-Acetyl Semax Amidate is a double-capped Semax analogue (N-acetyl + C-terminal amide) with a PubChem deposit (CID 172638603) but no identified peer-reviewed pharmacology, safety, or efficacy study of that exact molecule. Russian Semax approval and parent Semax data must not be transferred to this variant.

Body & signals →

No receptor relationship mapped here yet. This does not mean the molecule has no biological effects.

Review pending

Contents6

Editorial review pending — noindex

This page remains under independent editorial review (reviewPending). Visible but noindexed. Educational reference only.

No peer-reviewed data on this exact analog

N-Acetyl Semax Amidate (double-capped) has no identified peer-reviewed pharmacology, toxicology, or clinical study under that exact identity. Parent Semax evidence and Russian registration do not transfer. Vendor “better Semax” claims are not evidence.

Section 1 of 6Overview

Overview

N-Acetyl Semax Amidate (NA-Semax Amidate) is a synthetic Semax analogue with both an N-terminal acetyl and a C-terminal amide. PubChem CID 172638603 lists formula C₃₉H₅₄N₁₀O₁₀S, MW 855.0, and CAS synonym 2920938-90-3. It is sold as a research chemical, not as a registered medicine in any jurisdiction identified in the 2026-10-07 dossier.

Section 2 of 6Parent vs this variant

Parent vs this variant

	Semax (parent)	N-Acetyl Semax Amidate
Caps	Free N- and C-termini	Ac- … -NH₂
Formula / MW	C₃₇H₅₁N₉O₁₀S · ~813.9	C₃₉H₅₄N₁₀O₁₀S · 855.0
PubChem	CID 9811102	CID 172638603
Regulatory	Registered in Russia (intranasal); not FDA/EMA	None identified
Evidence	Limited mostly Russian human + preclinical	No peer-reviewed study of this exact molecule

PubChem synonyms that say only “N-acetyl semax” can blur Ac-only vs amidate — this page means the double-capped CID 172638603 entity.

Section 3 of 6Nearby papers (not this molecule)

Nearby papers (not this molecule)

Magrì et al., 2016 (PMID 27586814)

N-terminal acetylation of Semax vs Semax: Cu(II)/Zn(II) coordination and SH-SY5Y cell protection. Acetylation changed Cu complexes; Ac-Semax did not protect cells against Cu-induced toxicity where Semax did — free N-terminus mattered in that model. Applies to N-acetyl, not a documented C-amidate. It contradicts naive “acetyl = better neuroprotection” marketing for that endpoint.

Shevchenko et al., 2013 (PMID 23652441)

Lab stability of “Semax acetyl” against proteolysis — not human effect, not documented double-cap.

Vanhee et al., 2020 (PMID 31667971)

Analytical/forensic context for seized “cognitive enhancing research peptides” — market presence, not efficacy.

PubMed queries for the exact product name found no clinical or in-vivo pharmacology of the double-capped amidate (dossier cut).

Section 4 of 6Claims vs evidence

Claims vs evidence

Claim	Assessment
Double-capped Semax analogue (Ac + NH₂)	Supported chemically (PubChem)
Better / longer / stronger Semax	Not verified
Increased metabolic stability	Hypothesis / Ac-only lab — not double-cap human PK
BDNF / nootropic effects “as Semax”	Extrapolation from parent
Ac-form preserves Cu protection	Contradicted in cell study (PMID 27586814) for Ac-only
FDA/EMA/RU approved	False for the variant
Vendor dose = clinical dose	Reject

Section 5 of 6Related pages

Parent (do not copy dose/approval here): Semax
Related Selank-line research chemical: N-Acetyl Selank Amidate

Section 6 of 6What this page intentionally omits

What this page intentionally omits

Any dose or “protocol”
Copying ГРЛС / Semax study results onto this analog
Equating Ac-only papers with the amidate product

References6

References

1.
PubChem CID 172638603 — N-Acetyl Semax Amidate source
2.
PubChem CID 9811102 — Semax (parent) source
3.
N-terminal acetylation of Semax and Cu(II)/Zn(II) coordination — cell study — Magrì A, et al., Journal of Inorganic Biochemistry, 2016. source
4.
Stability of Semax acetyl against proteolysis (lab) — Shevchenko KV, et al., Doklady Biological Sciences, 2013. source
5.
Putative cognitive-enhancing research peptides in seizures (analytical) — Vanhee C, et al., 2020. source
6.
PeptideInfo — Semax (parent) source

Frequently asked questions4

Frequently asked questions

What is N-Acetyl Semax Amidate?: N-Acetyl Semax Amidate is a double-capped Semax analogue (N-acetyl + C-terminal amide) with a PubChem deposit (CID 172638603) but no identified peer-reviewed pharmacology, safety, or efficacy study of that exact molecule. Russian Semax approval and parent Semax data must not be transferred to this variant.
Is N-Acetyl Semax Amidate approved as a medicine, and where?: The regulatory review of N-Acetyl Semax Amidate is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.
What is N-Acetyl Semax Amidate studied for?: Research has examined Peptide capping / metabolic stability hypotheses (unverified for this exact analog) and Parent Semax BDNF/neuroprotection literature — see Semax page; not transferable by default. Being studied for an area does not mean it is proven or approved for it.
Does N-Acetyl Semax Amidate have human clinical trials?: The evidence review of N-Acetyl Semax Amidate is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. The editorial review of N-Acetyl Semax Amidate is incomplete. Source-supported findings and remaining uncertainties are stated in the article; review status does not certify approval, safety or suitability for use. Consult a qualified healthcare professional before making health decisions.

References

Frequently asked questions

Related in Nootropic & Neuropeptides